BIIB
Biogen Inc.
$201.80
▼ -0.57%
−$1.15
NASDAQ · Healthcare · Drug Manufacturers - General
· price updated 9h ago
Biogen Inc.
BIIB · NASDAQ · Healthcare · Drug Manufacturers - General · price updated 9h ago
$201.80
▼ -0.57% · −$1.15 today
AI research · $201.80
Track BIIB for continuous AI research
price position
Where BIIB sits now
52-week range
Low$123.38
High$219.72
Today $201.80
RSI (14)
47.6Neutral
03070100
fundamentals
Business quality and valuation
Operating record
What the business has actually produced
Revenue
Capital structure
Cash versus debt
Cash & investments$1.3B
Total debt$8.4B
Net cash after debt$-7.1B
Valuation
What the market charges
Forward P/E
Price against expected earnings
Favorable · 26% below Sector avg · favorable
15.27x
Price / sales
Value assigned to each sales dollar
Strong · Under 3x annual sales
2.99x
Price / FCF
Price against free cash generation
Strong · Under 20x free cash flow
11.12x
EV / EBITDA
Operating value including debt
Reasonable · Between 12x and 22x EBITDA
17.09x
Quality
How efficiently it compounds
ROIC
Return earned on invested capital
Reasonable · An 8% to 15% return on capital
8.9%
ROE
Profit generated from shareholder equity
Needs attention · Lagging most sector peers
4.6%
Debt / equity
Balance-sheet leverage
Favorable · Exceptional vs sector peers
0.44x
Current ratio
Short-term assets against liabilities
Strong · Comfortable short-term liquidity
1.87x
Geographic mix
Jun 30, 2026United States37.8% · $3.8B
International33.5% · $3.4B
Other28.7% · $2.9B
Selected financial data sourced from StockAnalysis and refreshed weekly. Figures may be delayed and are for research context, not investment advice.
peer comparison
How BIIB compares
| company | mkt cap | P/E | rev growth | score |
|---|---|---|---|---|
| $29.99B | 35.9 | +0.3% | 59 |
 | $10.69B | 18.4 | +23.5% | 78 |
 | $4.88B | 20.3 | +10.3% | 77 |
 | $31.49B | 32.9 | +15.5% | 77 |
 | $1.08T | 41.4 | +47.4% | 76 |
US stock research
About Biogen Inc. (BIIB) stock
Biogen Inc. tracked in the US core universe. BIIB was -0.6% in the latest available session at $201.80. Its reported market value was $29.99B with a trailing P/E of 35.9. Latest reported revenue was $10.03B, changing +0.3% year over year, with $834.60M in net income.
Market snapshot updated Aug 3, 2026, 7:59 PM UTC.
- Latest available price
- $201.80
- Day change
- -0.6%
- Market cap
- $29.99B
- P/E (TTM)
- 35.9
- Revenue growth
- +0.3%
- Industry
- Drug Manufacturers - General